LeMaitre Vascular (NASDAQ:LMAT) Issues Earnings Results

LeMaitre Vascular (NASDAQ:LMAT) announced its earnings results on Tuesday. The medical instruments supplier reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02, FiscalAI reports. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The business had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. During the same period in the prior year, the company earned $0.48 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular updated its FY 2026 guidance to 2.930-3.080 EPS and its Q2 2026 guidance to 0.790-0.840 EPS.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Strong Q1 and raised full‑year outlook: Q1 delivered 11% sales growth, a 72.7% gross margin and 42% EPS growth, and the company affirmed $280M full‑year revenue guidance (≈12% organic growth) while increasing margin and EPS targets.
• Artegraft is a major growth engine: Artegraft sales rose 36% in Q1 and is now the largest product—plans include international filings (Health Canada approval; launches H2‑2026; Korea/Brazil/Vietnam/India targeted in 2027), filing for longer graft packaging in H2‑2026 (first longer‑graft sales possible H2‑2027), and an FDA pre‑submission for a Quick‑Stick AV access claim.
• Operational and financial strength: Gross‑margin expansion was driven by pricing, favorable mix (higher‑margin Artegraft) and manufacturing efficiencies; cash from operations was $15M, cash/securities were $367M, and the company continues dividends and targeted commercial investment.
• RestoreFlow and regulatory timing are mixed: RestoreFlow grew 25% in Q1 with Germany distribution starting Q2 and Ireland approval expected H2 pending audit; multiple EU and Australia filings are planned but some European implants and warehousing validations have delayed near‑term ramp, leaving timing risk.

LeMaitre Vascular Price Performance

Shares of LMAT traded up $0.47 during mid-day trading on Tuesday, reaching $112.00. The stock had a trading volume of 225,462 shares, compared to its average volume of 173,958. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of 44.62, a PEG ratio of 3.21 and a beta of 0.60. LeMaitre Vascular has a 12 month low of $78.35 and a 12 month high of $118.01. The business has a fifty day moving average of $109.28 and a 200 day moving average of $94.17. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th were given a $0.25 dividend. The ex-dividend date was Thursday, March 12th. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 39.84%.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 150,000 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $106.76, for a total value of $16,014,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,532,304 shares in the company, valued at $163,588,775.04. This represents a 8.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the transaction, the insider owned 6,677 shares of the company’s stock, valued at approximately $736,406.33. The trade was a 13.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 215,438 shares of company stock worth $23,062,911 over the last three months. 7.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds and other institutional investors have recently modified their holdings of LMAT. EverSource Wealth Advisors LLC bought a new position in shares of LeMaitre Vascular during the second quarter worth $47,000. Geneos Wealth Management Inc. boosted its position in shares of LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares during the last quarter. Quarry LP boosted its position in shares of LeMaitre Vascular by 267.2% during the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after acquiring an additional 529 shares during the last quarter. Kestra Advisory Services LLC bought a new position in shares of LeMaitre Vascular during the fourth quarter worth $68,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of LeMaitre Vascular during the fourth quarter worth $80,000. Institutional investors own 84.64% of the company’s stock.

Trending Headlines about LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Earnings beat and year-over-year EPS growth — LMAT reported Q1 EPS of $0.68 vs. the Zacks consensus $0.66 and $0.48 a year ago, indicating margin strength and operating leverage. LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
• Positive Sentiment: Management raised EPS guidance — LMAT set Q2 2026 EPS guidance of $0.79–$0.84 (above consensus $0.76) and FY2026 EPS guidance of $2.93–$3.08 (above consensus ~$2.90), signaling confidence in demand and near-term profitability. View Press Release
• Positive Sentiment: Dividend declared — the company announced a quarterly cash dividend of $0.25/share, which supports income-focused investors and can be viewed as a sign of cash-generative business. LeMaitre Q1 2026 Financial Results
• Positive Sentiment: Strong profitability metrics — Q1 net margin (~23.1%) and ROE (~14.7%) underline efficient operations and support the elevated EPS outlook. View Press Release
• Neutral Sentiment: Revenue roughly in line with expectations — Q1 revenue was $66.55M versus consensus ~$66.67M, effectively in line; this tempers but does not negate the EPS beat. LeMaitre (NASDAQ:LMAT) Posts Q1 CY2026 Sales In Line With Estimates
• Neutral Sentiment: Revenue guidance band roughly matches consensus — FY revenue guidance $277M–$283M brackets street estimates (~$279.5M), so upside is more EPS-driven than revenue-driven at this point. View Press Release
• Negative Sentiment: Minor revenue shortfall vs. consensus — Q1 revenue missed by about $0.12M (66.55M vs. 66.67M), which is immaterial in isolation but worth watching if the trend continues. View Press Release

Analyst Ratings Changes

A number of analysts have commented on LMAT shares. Weiss Ratings raised shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Barrington Research upped their target price on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $105.80.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.